Brad Sorenson (Providence Therapeutics)
ArticleAn approach to mRNA vaccine development in the wake of COVID-19
Brad Sorenson, CEO of Providence Therapeutics, shares the future developments and exciting potential of mRNA therapies, including improved efficacy and wider access to vaccines, and future promise for cancer treatment.